[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![NattaCop Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1487028804971155457.png) TheUrbanFarmer [@NattaCop](/creator/twitter/NattaCop) on x 1132 followers
Created: 2025-07-21 20:18:56 UTC

$ocgn Luxturna treated XXX% of the RP market, that’s a global population of under 10K patients. They still did $120M in year one, got acquired for $1.4B, then later bought by Roche for $4.8B for a one mutation product…

Now compare that to Ocu400/410/410ST, which are gene agnostic and target broad IRD populations in RP, GA and Stargardt. Just Ocu410ST alone is going after a market 30x–50x the size Luxturna targeted…

Factor in FDA reforms cutting BLA reviews to X months, orphan pricing now securing prices at $1.25M+ no matter how many diseases a drug treats, and rewards like priority review vouchers that sell for $100M+…

And everything should be crystal clear.

We’re not holding another Luxturna. We’re holding something magnitudes bigger than anything this market has ever seen.

Nothing compares to what we own. 💯📠🍻🐂

![](https://pbs.twimg.com/media/GwaFqi9bkAA0j6u.jpg)

XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1947390858262942006/c:line.svg)

**Related Topics**
[ocgn](/topic/ocgn)
[$48b](/topic/$48b)
[$14b](/topic/$14b)
[$120m](/topic/$120m)
[10k](/topic/10k)
[rp](/topic/rp)
[$ocgn](/topic/$ocgn)

[Post Link](https://x.com/NattaCop/status/1947390858262942006)